Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Condition: Lymphoma
MeSH terms: Lymphoma
Intervention: filgrastim; carboplatin; carmustine; cyclophosphamide; cytarabine; etoposide; ifosfamide; melphalan; bone marrow ablation with stem cell support; peripheral blood stem cell transplantation; radiation therapy
Intervention MeSH terms: Cytarabine; Cyclophosphamide; Melphalan; Ifosfamide; Carmustine; Carboplatin; Etoposide
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 118.0
Sex: All
Maximum age: 120 Years
Healthy volunteers: No
Keywords: recurrent adult Hodgkin lymphoma; recurrent/refractory childhood Hodgkin lymphoma

Summary:

      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell
      transplantation may be able to replace immune cells that were destroyed by chemotherapy and
      radiation therapy used to kill tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in
      treating patients with refractory or relapsed Hodgkin's lymphoma.
    

Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed residual or relapsed Hodgkin's lymphoma following
             conventional dose standard chemotherapy

          -  Presence of the following prognostic factors are allowed:

               -  B symptoms (fever, weight loss, night sweats)

               -  Extranodal disease

               -  Complete remission of less than 1 year duration

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease

          -  No chronic active or persistent hepatitis

        Renal:

          -  No history of chronic renal insufficiency

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

          -  No unstable angina

          -  No significant cardiac arrhythmias other than chronic atrial fibrillation

          -  Ejection fraction at least 50%

        Pulmonary:

          -  DLCO at least 50%

        Other:

          -  No uncontrolled infection

          -  HIV negative

          -  At least 5 years since prior malignancy except:

               -  Curatively treated cutaneous basal cell carcinoma

               -  Carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Fertile women must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  Must have failed conventional dose standard chemotherapy